Design Therapeutics, Inc. 8-K Report: Key Updates for January 13, 2025

Based on the provided section of the financial report, here are the key pieces of information extracted:

1. Entity Information:

• Name: Design Therapeutics, Inc.
• CIK (Central Index Key): 0001807120
• SEC File Number: 001-40288
• EIN (Employer Identification Number): 82-3929248
• Address: 6005 Hidden Valley Road, Suite 110, Carlsbad, CA 92011
• Phone Number: (858) 293-4900

2. Report Type:

• Form: 8-K (which is used for current reports by companies to announce major events that shareholders should know about)

3. Report Period:

• Start Date: January 13, 2025
• End Date: January 13, 2025

4. Securities Information:

• Common Stock Par Value: $0.0001 per share
• Stock Symbol: DSGN
• Exchange: NASDAQ

5. Filing Context:

• The document is part of an XBRL (eXtensible Business Reporting Language) filing, which is a standardized format for financial data.

Insights:

• The report is a current event filing (Form 8-K), suggesting that Design Therapeutics, Inc. may have significant news or events to disclose as of January 13, 2025.
• The company is publicly traded on NASDAQ under the ticker symbol DSGN, indicating it operates in a regulated environment and must comply with SEC filing requirements.
• The specific date of the report (January 13, 2025) could indicate an immediate event or announcement that may be relevant for investors and stakeholders.
• The low par value of the common stock could signal a startup or growth-stage company, which is common in biotech firms.

This information can provide stakeholders with insights into the company's operational status and financial health as of the reporting date.